Novo Nordisk Faces Pivotal Moment in Oral Weight-Loss Drug Race

Novo Nordisk releases Wegovy pill data ahead of Lilly's launch as analysts cut targets citing competition and pipeline risks. Key market dynamics explained.

The battle for supremacy in the lucrative oral GLP-1 drug market is intensifying. Novo Nordisk has strategically released new comparative data for its Wegovy pill just one day before Eli Lilly’s competing product, Foundayo, launches in the U.S. market on April 6th. This timing underscores a critical struggle between the two pharmaceutical giants to control the narrative surrounding next-generation weight-loss treatments.

Analyst Sentiment Reflects Mounting Challenges

Market experts are adopting a cautious stance toward Novo Nordisk’s near-term prospects. Morgan Stanley recently upgraded the company’s rating from “Underweight” to “Equal Weight,” setting a price target of $40—a move viewed as restrained. The bank identifies 2026 as a transitional year, anticipating heightened competition following Lilly’s planned launch of its oral drug, Orforglipron, in the second quarter.

Further adjustments came from analyst Thibault Boutherin, who reduced his price target to 250 Danish kroner from 270 DKK. He cited medium-term growth uncertainty and risks related to the patent protection for semaglutid, Novo’s key compound. According to his analysis, these risks are now more fully reflected in the share price following its decline after the REDEFINE-4 study data release. J.P. Morgan took an even more conservative view, slashing its June 2027 price forecast for Novo Nordisk (NVO) to 250 DKK from 350 DKK. This revision was partly attributed to disappointing data for another of the company’s pipeline drugs, CagriSema.

Wegovy Pill Data Shows Mixed Profile

At the Obesity Medicine Association’s annual meeting in San Diego, Novo Nordisk presented findings from its ORION study. A population-adjusted indirect comparison analysis indicated that its oral Wegovy tablet (semaglutid 25 mg) achieved approximately 3.2 percentage points more weight loss than Lilly’s 36 mg Orforglipron. The data also suggested that patients discontinued Orforglipron treatment due to gastrointestinal side effects 14 times more frequently.

However, this analysis relies solely on previously published study data and does not introduce new clinical evidence. A significant practical drawback remains: patients taking the Wegovy pill must wait 30 minutes before eating or drinking each day—a restriction that does not apply to Lilly’s Foundayo.

Pipeline and Prescription Trends Under Scrutiny

The combined drug CagriSema, a weekly injection of cagrilintid and semaglutid, represents Novo Nordisk’s most important regulatory milestone ahead of its Capital Markets Day in September 2026. J.P. Morgan has lowered its revenue projections for the Novo Nordisk group for the period 2026-2030 by 2% to 16%, explicitly pointing to weak CagriSema study results as a key reason.

The company’s shares currently trade about 28% below their level at the start of the year, a significant retreat from their 52-week high. In the short term, weekly prescription data for the Wegovy pill will likely serve as a crucial indicator. Some market observers are already noting signs that physicians may be holding back on new prescriptions, possibly waiting to see initial market performance data for Lilly’s Foundayo before making decisions.